American Journal of Kidney Diseases
Volume 57, Issue 4 , Pages 542-546 , April 2011

The 2011 ESRD Prospective Payment System: An Uncontrolled Experiment

  • Wolfgang C. Winkelmayer, MD, ScD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Wolfgang C. Winkelmayer, MD, MPH, ScD, Division of Nephrology, Stanford University School of Medicine, 780 Welch Rd, Ste 106, Palo Alto, CA 94304
    • ,
  • Glenn M. Chertow, MD, MPH

References 

  1. Department of Health and Human ServicesCenters for Medicare & Medicaid Services. Medicare Program; End-Stage Renal Disease Prospective Payment System. Fed Regist. 2010;75(155):49029–49214
  2. US Renal Data System. Clinical indicators and preventive health. In: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease and Chronic Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009;p. 259–268
  3. US Renal Data System. Costs of ESRD. In: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease and Chronic Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009;p. 335–342
  4. Medicare Improvements for Patients and Providers Act of 2008. Medicare, Provisions Relating to Part B, Other Payment and Coverage Improvements. Public L No. 110-275, §153(a) (2008).
  5. Department of Health and Human ServicesCenters for Medicare & Medicaid Services. Medicare Program (End-Stage Renal Disease Quality Incentive Program). Fed Regist. 2011;76:628–646
  6. Roach JL, Turenne MN, Hirth RA, Wheeler JR, Sleeman KS, Messana JM. Using race as a case-mix adjustment factor in a renal dialysis payment system: potential and pitfalls. Am J Kidney Dis. 2010;56:928–936
  7. Chertow GM, Levin NW, Beck GJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363:2287–2300
  8. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  9. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis (Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients). N Engl J Med. 1998;339:578–583
  10. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984
  11. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006;47:644–654
  12. Shahidi NT. Androgens and erythropoiesis. N Engl J Med. 1973;289:72–80
  13. Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab. 1994;20:97–102
  14. Mazzaferro S, Pasquali M, Ballanti P, et al. Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study. Miner Electrolyte Metab. 1994;20:122–129
  15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–S130
  16. Schreiber B. Levocarnitine and dialysis: a review. Nutr Clin Pract. 2005;20:218–243
  17. Winkelmayer WC, Liu J, Kestenbaum B. Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. Clin J Am Soc Nephrol. 2011;6:176–183
  18. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363:609–619
  19. Fuller TC, Delmonico FL, Cosimi B, Huggins CE, King M, Russell PS. Impact of blood transfusion on renal transplantation. Ann Surg. 1978;187:211–218
  20. US Government Accountability Office. End-Stage Renal Disease—CMS Should Monitor Access to and Quality of Dialysis Care Promptly after Implementation of New Bundled Payment System (GAO-10-295). http://www.gao.gov/new.items/d10295.pdfMarch 2010;Accessed January 7, 2011

 Originally published online February 18, 2011.

 This article is part of a series in the April 2011 issue of AJKD that explores the 2011 final rule for the Medicare ESRD prospective payment system.

PII: S0272-6386(11)00041-2

doi: 10.1053/j.ajkd.2011.01.013

American Journal of Kidney Diseases
Volume 57, Issue 4 , Pages 542-546 , April 2011

Article Tools